Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

369 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch C, Cameron D, Mano M, Pedrini JL, Veronesi A, Mendiola C, Pluzanska A, Semiglazov V, Vrdoljak E, Eckart MJ, Shen Z, Skiadopoulos G, Procter M, Pritchard KI, Piccart-Gebhart MJ, Bell R; Herceptin Adjuvant (HERA) Trial Study Team. Gianni L, et al. Among authors: azambuja e. Lancet Oncol. 2011 Mar;12(3):236-44. doi: 10.1016/S1470-2045(11)70033-X. Epub 2011 Feb 25. Lancet Oncol. 2011. PMID: 21354370 Clinical Trial.
Current management of ovarian carcinosarcoma.
Mano MS, Rosa DD, Azambuja E, Ismael G, Braga S, D'Hondt V, Piccart M, Awada A. Mano MS, et al. Among authors: azambuja e. Int J Gynecol Cancer. 2007 Mar-Apr;17(2):316-24. doi: 10.1111/j.1525-1438.2006.00760.x. Int J Gynecol Cancer. 2007. PMID: 17362309 Free article. Review.
Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial.
Pestalozzi BC, Francis P, Quinaux E, Dolci S, Azambuja E, Gelber RD, Viale G, Balil A, Andersson M, Nordenskjöld B, Gnant M, Gutierrez J, Láng I, Crown JP, Piccart-Gebhart M; BIG 02-98 Collaborative Group. Pestalozzi BC, et al. Among authors: azambuja e. Ann Oncol. 2008 Nov;19(11):1837-41. doi: 10.1093/annonc/mdn385. Epub 2008 Jun 18. Ann Oncol. 2008. PMID: 18562328 Free PMC article. Clinical Trial.
Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.
Fernández-Cuesta L, Oakman C, Falagan-Lotsch P, Smoth KS, Quinaux E, Buyse M, Dolci MS, Azambuja ED, Hainaut P, Dell'orto P, Larsimont D, Francis PA, Crown J, Piccart-Gebhart M, Viale G, Leo AD, Olivier M. Fernández-Cuesta L, et al. Among authors: azambuja ed. Breast Cancer Res. 2012 May 2;14(3):R70. doi: 10.1186/bcr3179. Breast Cancer Res. 2012. PMID: 22551440 Free PMC article. Clinical Trial.
Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab.
Debien V, Marta GN, Agostinetto E, Sirico M, Jacobs F, Molinelli C, Moreau M, Paesmans M, De Giorgi U, Santoro A, Taylor D, Duhoux FP, Botticelli A, Barchiesi G, Speranza I, Lambertini M, Wildiers H, Azambuja E, Piccart M. Debien V, et al. Among authors: azambuja e. Crit Rev Oncol Hematol. 2023 Oct;190:104089. doi: 10.1016/j.critrevonc.2023.104089. Epub 2023 Aug 9. Crit Rev Oncol Hematol. 2023. PMID: 37562696 Review.
Body mass index and weight changes in patients with HER2-positive early breast cancer: A sub-analysis of the APHINITY trial.
Dauccia C, Alice Franzoi M, Martel S, Agbor-Tarh D, Fielding S, Piccart M, Bines J, Loibl S, Di Cosimo S, Vaz-Luis I, Di Meglio A, Del Mastro L, Gombos A, Desmedt C, Jerusalem G, Reaby L, Pienkowski T, Lambertini M, Agostinetto E, Azambuja E; APHINITY Steering Committee and Investigators. Dauccia C, et al. Among authors: azambuja e. Eur J Cancer. 2025 Jun 18;223:115489. doi: 10.1016/j.ejca.2025.115489. Epub 2025 May 8. Eur J Cancer. 2025. PMID: 40367619 Clinical Trial.
Chemoprevention for breast cancer.
Bozovic-Spasojevic I, Azambuja E, McCaskill-Stevens W, Dinh P, Cardoso F. Bozovic-Spasojevic I, et al. Among authors: azambuja e. Cancer Treat Rev. 2012 Aug;38(5):329-39. doi: 10.1016/j.ctrv.2011.07.005. Cancer Treat Rev. 2012. PMID: 21856081 Review.
369 results